Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 1351 to 1365 of 2854 results for process

  1. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

  2. IHI and H2020 Grant funded projects

    IMI and H2020 Grant funded projects with NICE

  3. Contraception: advice for people with epilepsy (IND117)

    This indicator covers the percentage of women with epilepsy who are aged 18 or over, but under 45, who are taking antiseizure medications and have a record of being given information and advice in the previous 12 months about pregnancy or conception, or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM71

  4. Diabetes: blood pressure (without moderate or severe frailty) (IND249)

    This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233

  5. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.

  6. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.

  7. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

  8. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

  9. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  05 August 2026

  10. HIV: routine blood tests (IND211)

    This indicator covers the percentage of adults and young people at a GP surgery in an area of high or extremely high HIV prevalence who have not had an HIV test in the last 12 months, who are having a blood test and receive an HIV test at the same time. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM190

  11. HIV: testing at registration (IND210)

    This indicator covers the percentage of adults and young people newly registered with a GP in an area of high or extremely high HIV prevalence who receive an HIV test within 3 months of registration. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM189

  12. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date:  14 April 2027

  13. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]

    In development Reference number: GID-TA11416 Expected publication date:  08 July 2026

  14. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

  15. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84